|
General |
Study Status |
Completed |
Application Number / Requirement Number |
P160013 S002/ PAS001 |
Date Original Protocol Accepted |
05/31/2019
|
Date Current Protocol Accepted |
 
|
Study Name |
EXPAND Continuation PAS
|
Device Name |
Organ Care System (OCS™) Lung System
|
General Study Protocol Parameters |
Study Design |
Prospective Cohort Study
|
Data Source |
New Data Collection
|
Comparison Group |
No Control
|
Analysis Type |
Descriptive
|
Study Population |
Transit. Adolescent A (distinctively) : 18-21 yrs,
Transit. Adolescent B (as adults) : 18-21 yrs,
Adult: >21
|
Detailed Study Protocol Parameters |
Study Objectives |
Single-arm, prospective, observational post-approval data collection for subjects enrolled and transplanted in the Lung EXPAND clinical trial. 5- Year follow-up data will be collected from UNOS for US transplanted patients and directly from the clinical sites in OUS patients
|
Sample Size |
All 79 subjects in the Lung EXPAND trial will be re-consented for permission to access to their follow-up data. Only patients who provide informed consent are enrolled in the Continuation PAS.
|
Key Study Endpoints |
The primary effectiveness endpoint is Bronchiolitis Obliterans Syndrome (BOS)-free survival (freedom from BOS and mortality) through 5 years after transplantation. Other study endpoints include: Survival (freedom from mortality) through 5 years after transplantation Freedom from BOS through 5 years after transplantation
|
Follow-up Visits and Length of Follow-up |
5 years
|
Interim or Final Data Summary |
Actual Number of Patients Enrolled |
79 patients from the EXPAND pivotal trial
|
Actual Number of Sites Enrolled |
8 sites
|
Patient Follow-up Rate |
5-year follow-up rate: 98% (53/54)
|
Final Safety Findings |
There were 26 deaths and 1 retransplantation over 5 years post initial lung transplant.
|
Final Effect Findings |
5-year rate of BOS-free survival is 55% (BOS defined as grade 1, 2, or 3) 5-year rate of patient survival is 68% 5-year rate of freedom from BOS is 76% (BOS defined as grade 1, 2, or 3)
|
Study Strengths & Weaknesses |
Despite the small sample size in this study, the long-term follow-up was high, with 5-year data collected in 53 of the 54 patients (98%) who were eligible for follow-up. These results need to be replicated in larger studies.
|
Recommendations for Labeling Changes |
Yes
|